• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction

byConstance Wu
December 14, 2019
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Colchicine given to patients after a myocardial infarction led to a significantly lower risk of death from cardiovascular causes, resuscitations, myocardial infarctions, stroke, and hospitalizations for angina.

2. The main adverse events from colchicine, as compared to placebo, were diarrhea, nausea, and pneumonia.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The American Heart Association and the American Stroke Association guidelines recommend statins to be used in patients following ischemic stroke. Prior studies have shown a decrease in cardiovascular events when using an inflammatory modulator, but it came with the risk of increased infection rates.  This randomized-controlled trial examined the effects and long-term efficacy of low-dose colchicine, an inexpensive anti-inflammatory medication, on cardiovascular outcomes. 0.5mg of daily colchicine was given to patients within 30 days after a myocardial infarction and followed for about 20 months. Overall, there was a decreased risk of cardiovascular events among the participants taking colchicine, including death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, and hospitalization for angina leading to coronary revascularization. There was an increased rate of diarrhea, nausea, and pneumonia among the colchicine group, as compared to the placebo group. This large, longitudinal study included a majority of patients that received aspirin, another antiplatelet agent, statin, and PCI (percutaneous coronary intervention) in addition to colchicine.  Further research is needed to study more patients and determine the longer-term efficacy and safety of colchicine in preventing cardiac events.

Click to read the study in NEJM

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Colchicine not beneficial after acute myocardial infarction for reducing cardiovascular events

De-escalating dual antiplatelet therapy may lower major bleeding risk following drug-eluting stent implantation

Optical coherence tomography-guided angioplasty reduces adverse events compared to angiography guidance

Tags: cardiovascular eventscolchicineischemic heart diseasepercutaneous coronary intervention (PCI)
Previous Post

Rectal indomethacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients

Next Post

#VisualAbstract: A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke

RelatedReports

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study
Cardiology

Colchicine not beneficial after acute myocardial infarction for reducing cardiovascular events

March 3, 2025
Stent type may not be related to adverse cardiac events after surgery
Cardiology

De-escalating dual antiplatelet therapy may lower major bleeding risk following drug-eluting stent implantation

February 17, 2025
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease
Cardiology

Optical coherence tomography-guided angioplasty reduces adverse events compared to angiography guidance

October 1, 2024
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease
Cardiology

Ticagrelor monotherapy reduces bleeding risk compared to dual antiplatelet therapy for patients following coronary stenting

September 25, 2024
Next Post
#VisualAbstract: A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke

#VisualAbstract: A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke

Tonsillectomy may have short-term benefits in recurrent throat infection

More than half of pediatric residents meet criteria for burnout

Pre-exposure prophylaxis (PrEP) effective in preventing HIV infection in high-risk gay men

Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early acetaminophen use reduces mortality risk in patients with sepsis-associated encephalopathy
  • Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
  • 2 Minute Medicine Rewind June 30, 2025
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.